Diagnosis and treatment of palindromic rheumatism— An updated review
محل انتشار: فصلنامه تحقیقات روماتولوژی، دوره: 11، شماره: 3
سال انتشار: 1405
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 65
فایل این مقاله در 6 صفحه با فرمت PDF قابل دریافت می باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_RHRE-11-3_002
تاریخ نمایه سازی: 14 آبان 1405
چکیده مقاله:
Palindromic rheumatism (PR) is a distinctive episodic arthropathy characterized by recurrent, self-limiting attacks of mono- or oligoarthritis lasting less than ۷۲ hours, with complete resolution between flares and no residual joint damage. Although first described over ۷۵ years ago, PR remains diagnostically challenging due to its intermittent nature and lack of specific biomarkers. The diagnosis is clinical, requiring exclusion of other causes of intermittent arthritis, including crystal-induced, infectious, and systemic autoimmune diseases. Serologically, anti-CCP antibodies are detectable in ۵۰–۷۰% of patients and rheumatoid factor in ۳۰–۶۰%, with positivity conferring a higher risk of progression to rheumatoid arthritis (RA), which occurs in approximately one-third of patients, predominantly within the first decade. No controlled trials or formal treatment guidelines exist; management is therefore empirical. Antimalarials, particularly hydroxychloroquine, are considered first-line therapy and have been shown to reduce attack frequency and delay progression to RA. Methotrexate and leflunomide serve as add-on therapies in refractory cases, while rituximab is a biologic agent reported for use in treatment-resistant patients. Emerging evidence suggests that iguratimod, a novel synthetic disease-modifying antirheumatic drug, may also be effective. A step-up combination strategy targeting complete remission has demonstrated favorable outcomes, with ۷۰% of patients achieving remission and only ۹% progressing to RA in long-term follow-up. PR likely represents a spectrum between self-limited recurrent arthritis and established RA. Future research should prioritize randomized controlled trials to establish evidence-based guidelines and identify predictive biomarkers.
کلیدواژه ها:
palindromic rheumatism ، treatment ، step-up combination therapy ، remission ، . Disease-modifying antirheumatic drug (DMARDs)
نویسندگان
- -
Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences.
مراجع و منابع این مقاله:
لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :